Sanofi(SNY)

PARIS, FrancePharmaceutical1 H-1B visas (FY2023)

View 953 open jobs Website LinkedIn Careers Page

Focus: Sanofi is a Paris-based Big Pharma company with 91,000 employees operating across small molecules, biologics, and vaccines spanning immunology, oncology, neurology, rare diseases, and vaccines. It is a publicly traded ($SNY) tier-one pharmaceutical manufacturer with global commercial scale.

Immunology Oncology Neurology Rare Diseases

Profile data last refreshed 11h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

91,000

Open Jobs

953+598 this month

Hot — 1601 jobs added in 30d

Net +598 (1601 new, 1003 removed). Aggressive expansion phase.

Should You Work at Sanofi?

AI assessment

Sanofi offers Big Pharma stability and global reach ideal for commercial, manufacturing, and regulatory professionals, but faces material patent cliff risk and pipeline execution questions that make it higher-risk for research scientists and early-career innovators betting on breakthrough catalysts.

Why Work Here

Scale and stability: 91,000-person organization with diversified therapeutic portfolio across five major areas and 501 active job openings, providing long-term career runway.

Data completeness

6/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

3 imminent

CAPRELSA

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

LANTUS SOLOSTAR

Insulin Analog

$3.2B

LOE Approaching

Sanofi's cash cow representing 49% of total revenue, but faces imminent generic competition and biosimilar erosion, creating urgent need for revenue replacement.

Help build intelligence for Sanofi

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Vaccine and rare disease leadership: Active pipeline in vaccines, Type 1 diabetes (Teplizumab Phase 2), rare lysosomal disorders (venglustat Phase 3), and oncology combinations, signaling innovation beyond legacy insulin products.

Commercial opportunity: 110 open Commercial roles plus 89 R&D positions indicate aggressive market expansion, especially post-obesity drug regret—strong upside for sales, marketing, and BD professionals.

Watch Out For

Severe patent cliff and revenue dependency: 49% of revenue from LANTUS (insulin glargine) with loss of exclusivity approaching; $523M in near-term LOE revenue at risk (RENVELA 2030, MULTAQ 2031), forcing pipeline-dependent growth.
Recent R&D restructuring and layoffs: April 2024 WARN filing for Cambridge MA R&D layoff signals portfolio rationalization; recent news headline 'No Target Number for Pipeline Cuts' indicates ongoing uncertainty in research productivity and job security.
Obesity drug market loss: Sanofi ceded obesity space to Hanmi; missing this blockbuster category (GLP-1 agonists) is a competitive strategic miss that may constrain innovation hires and stock upside.

Generated by Claude from Sanofi's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LANTUS

Insulin Analog

$736M

LOE Approaching

Legacy basal insulin formulation losing market share to newer analogs and GLP-1 agents; Part D spending reflects declining prescriber preference.

TOUJEO SOLOSTAR

Basal Insulin

$542M

Peak

Concentrated insulin analog offering niche patient segment with modest but stable commercial traction.

TOUJEO MAX SOLOSTAR

Basal Insulin

$489M

Peak

High-dose insulin formulation capturing smaller patient population; maintains steady revenue contribution.

MULTAQ

Antiarrhythmic

$409M

Peak4.6yr

Cardiology mainstay with 5+ years of patent protection remaining; $409M revenue makes it a top diversifier outside insulin, but faces generic cliff in 2031.

ACTHAR

Multiple sclerosis exacerbations

$378M

LOE Approaching

Specialty rare indication product with orphan characteristics, but no LOE date transparency suggests regulatory or market vulnerability.

AUBAGIO

Pyrimidine Synthesis Inhibitor

$354M

Peak7.7yr

Immunology asset with solid 8+ year patent runway; steady MS/rare disease revenue from differentiated mechanism.

REZUROCK

Chronic graft-versus-host disease

$146M

Peak15.7yr

Modern onco-immunology asset with long exclusivity tail (16+ years); rare disease indication supports premium pricing and career growth in cell therapy space.

RENVELA

Hyperphosphatemia

$114M

LOE Approaching

Nephrology-focused symptomatic therapy with modest revenue base; approaching LOE creates $114M revenue cliff risk.

RENVELA

Phosphate binding

$114M

Peak4.1yr

Secondary renal indication with declining trajectory; 2030-12 patent expiration adds to $523M total cliff exposure.

Pipeline & Clinical Trials

Investigational Procedures

Sphingomyelin Lipidosis

N/A

Clinical Trials (1)

NCT04106544A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

N/A

Efluelda® Pre-filled syringe

Influenza Immunization

N/A

Clinical Trials (1)

NCT07282795Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe

N/A

Kidney Information Network for Disease Research and Education

ESRD

N/A

Clinical Trials (1)

NCT03321604Kidney Information Network for Disease Research and Education

N/A

Observatory on Elderly Patients "Les S.AGES"

Diabetes Mellitus, Type 2

N/A

Clinical Trials (1)

NCT01065909Observatory on Elderly Patients "Les S.AGES"

N/A

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Optic Neuritis

N/A

a live attenuated chimeric JE vaccine

Japanese Encephalitis

N/A

Clinical Trials (2)

NCT02526550Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Phase 4

NCT02602652Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine

Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials

Peripheral Arterial Occlusive Disease

N/A

Clinical Trials (1)

NCT01135797Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials

N/A

Flublok Quadrivalent influenza vaccine RIV4

Influenza

N/A

Clinical Trials (1)

NCT04460781Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

N/A

Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registr

Acute Leukemia

N/A

Clinical Trials (2)

NCT01362972Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor

N/A

NCT01362985Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor

Bevacizumab

Lung Cancer

N/A

Clinical Trials (5)

NCT00208546Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Phase 3

NCT00335595Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients

AZD6244

Thyroid Cancer

N/A

DUPIXENT®

Asthma

N/A

Clinical Trials (5)

NCT04287608Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

N/A

NCT06099704Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

N/A

Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

Meningitis

N/A

Clinical Trials (4)

NCT01270503Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Phase 4

NCT00483574Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

Prostatic Neoplasms

N/A

Clinical Trials (1)

NCT01076751Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

N/A

RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment

Hypertension

N/A

Plerixafor

Bone Marrow / Autologous Transplants

N/A

Clinical Trials (5)

NCT02006225Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.

Phase 4

NCT05087212Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Dupilumab - Standard Dose

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

N/A

Clinical Trials (1)

NCT06892704Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

N/A

A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatmen

Asthma

N/A

Clinical Trials (1)

NCT05070663A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)

N/A

Nasopharyngeal sampling

Bordetella Pertussis, Whooping Cough

N/A

Clinical Trials (1)

NCT03388034Pertussis Immunization Programs in Low Income Countries - Ivory Coast

N/A

Sepraspray

Adhesion Prevention

N/A

Clinical Trials (3)

NCT00624390Sepraspray™ Laparoscopic Myomectomy Study

N/A

NCT00813397Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.

N/A

Brigham and Women's Rheumatoid Arthritis Sequential Study

Rheumatoid Arthritis

N/A

Alglucosidase alfa GZ419829

Glycogen Storage Disease Type II

N/A

Clinical Trials (1)

NCT04848779A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

N/A

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 m

Primary Hypercholesterolaemia and Mixed Dyslipidaemia

N/A

Clinical Trials (1)

NCT05129241Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

N/A

Advancing Integrated Therapies for Gaucher Disease

Gaucher Disease

N/A

Clinical Trials (1)

NCT07758816Advancing Integrated Therapies for Gaucher Disease

N/A

Blood sampling

Septic Shock

N/A

Clinical Trials (3)

NCT02638779REAnimation Low Immune Status Markers

N/A

NCT00929318Influence of Thyroid Hormones on the Woundhealing Process

N/A

intradermal pholcodine allergy test in cases

Neuromuscular Blocking Agents Anaphylaxis

N/A

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Medication Non-adherence

N/A

Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical

Heparin-induced Thrombocytopenia

N/A

Clinical Trials (1)

NCT00748839Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical

N/A

Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients

Acne

N/A

Clinical Trials (1)

NCT07411638Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients

N/A

Venous Thromboembolism Taskforce Audit Program

Venous Thrombosis

N/A

Clinical Trials (1)

NCT00535171Venous Thromboembolism Taskforce Audit Program

N/A

Observational study

Myopathy

N/A

Clinical Trials (5)

NCT00077662A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

N/A

NCT04618237Observational Study of Long-Term Joint Health Outcome in Hemophilia Patient

N/A

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

Healthy

N/A

Clinical Trials (1)

NCT02447627Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

N/A

6 Minute Walk Test

Aged

N/A

Delay between MS onset and introduction of first line DMT

C10.114.375.500

N/A

Clinical Trials (1)

NCT03308994Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration

N/A

Sepraspray

Abdominal Adhesions

N/A

Clinical Trials (1)

NCT00665730Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions

N/A

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Hematologic Disorder

N/A

Blood sample

Dermatitis Atopic

N/A

Clinical Trials (4)

NCT03784898Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Phase 4

NCT03849716Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in German

Chlamydia Trachomatis

N/A

Clinical Trials (1)

NCT07002047Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany

N/A

Alfuzosin

Kidney Stones

N/A

Clinical Trials (1)

NCT00583258A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones

N/A

Meningococcal

Meningitis

N/A

Clinical Trials (5)

NCT02591290Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Phase 4

NCT02864927Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Phase 4

Zolpidem CR

Dementia

N/A

Clinical Trials (1)

NCT00814502Zolpidem CR and Hospitalized Patients With Dementia

N/A

Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine

Arsenic--Toxicology

N/A

Clinical Trials (1)

NCT03930017Pregnancy, Arsenic and Immune Response

N/A

Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study

TTP - Thrombotic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT05950750Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study

N/A

Financial incentives for increasing physical exercise

Sedentary Lifestyle

N/A

Clinical Trials (1)

NCT01043757Financial Incentives for Increasing Exercise

N/A

Stamaril®

Yellow Fever

N/A

Clinical Trials (1)

NCT03541694Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea

N/A

Heparin Induced Thrombocytopenia: Pharmacoeconomics

Heparin Induced Thrombocytopenia (HIT)

N/A

Clinical Trials (1)

NCT00456001Heparin Induced Thrombocytopenia: Pharmacoeconomics

N/A

Screening DIVA - Diffuse Vascular Disease

Peripheral Vascular Diseases

N/A

Pediatric and Ambulatory Research in Infectious Diseases

Otitis

N/A

Quadrivalent Intradermal Influenza Vaccine

Pregnancy

N/A

Clinical Trials (1)

NCT02554409Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

N/A

Seprapack Sinus Dressing

Chronic Sinusitis

N/A

Clinical Trials (1)

NCT00140608Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery

N/A

Interview Prep Quick Facts

Portfolio: 298 approved products, 172 clinical trials

Top TAs: Oncology, Metabolic Diseases, Infectious Diseases

H-1B (2023): 1 approval

Publications: 50 in PubMed

Open Roles: 953 active jobs

Portfolio Health

Pre-Launch69 (23%)

Growth5 (2%)

Peak22 (7%)

LOE Approaching130 (44%)

Post-LOE72 (24%)

298 total products

Therapeutic Area Focus

Oncology

48 marketed767 pipeline

Metabolic Diseases

29 marketed398 pipeline

Infectious Diseases

24 marketed356 pipeline

Neurology

21 marketed145 pipeline

Hiring Trend

Actively Hiring

953

Open Roles

+503

Added

-392

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2024-04-29

— Cambridge, MA

Source: state DOL filings, aggregated via Big Local News

2 active drug shortages

April 2024 WARN filing for Cambridge MA R&D restructuring signals ongoing portfolio optimization and potential job losses in research operations.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Lipoprotein(a), smoking, and diabetes are additive but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome.

American journal of preventive cardiology

2027

PMID:42892971

NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody-antigen interactions.

NCT00508872Folfox-B Study for Patients With Colorectal Liver Metastases

Phase 2

NCT03992417Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

N/A

NCT00539032Immunology and Safety of Menactra® in Children in Saudi Arabia

Phase 3

NCT00103662Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Phase 3

NCT00778479Evaluation of the Safety of Sepraspray in Open Abdominal Surgery

N/A

NCT06469359Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)

N/A

NCT03147898Observational Study Describing the Immune Profile Induced By Pertussis Vaccines

N/A

NCT03643328Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients

N/A

NCT02633787Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Phase 4

Rare Diseases

11 marketed149 pipeline

Respiratory

25 marketed133 pipeline

Immunology

27 marketed125 pipeline

Cardiovascular

21 marketed112 pipeline

R&D roles carry elevated restructuring risk; April 2024 Cambridge layoff plus CEO commentary ('No Target Number for Pipeline Cuts') suggests continued rationalization cycles through 2026–2027.

mAbs

2026

PMID:41797001

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Sanofi(SNY)

Should You Work at Sanofi?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (48)

Key Products by Revenue

Other Products (24)

Pipeline & Clinical Trials

Recent News · Sanofi(10)

Open Jobs (953)

Launch Packaging lead

BioProcess Engineer

2027 Summer Intern EGDS Morristown NJ

Maintenance Technician

Supervisor Manufacturing

2027 Summer Intern Pharmacovigilance Scientist Swiftwater PA

Thought Leader Liaison Pulmonology Chicago IL

mRNA Analytical Development Senior Scientist

Strategic Account Manager - Dallas/Fort Worth

Production Data & Process Support Specialist

Area Business Manager - Allergy - Manhattan, NY

Area Business Manager - GI, GI Columbus

E4A Dupixent Business Partner Respiratory Diseases

Associate Director, Forecasting – Rare Disease (RD)

2027 Summer Co op Utility Engineering Swiftwater PA

Rheumatology Key Account Specialist, New England

Therapeutic Area Lead, Bone Marrow Transplant, New York

Contamination Control Specialist

B57 Prep-Tank Technician

Rheumatology Key Account Specialist, New York

US Senior Medical Director, Rare Hematology

Digital Consumer Experience Strategy & Research Lead

2027 Spring Post-Doctoral Fellowship Opportunities, Waltham, MA

Global Transplant Medical Lead, SOT

Global Transplant Medical Lead, HSCT

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Research Publications(10)